Eliezer Van Allen
About Eliezer Van Allen
- The introduction of Zytiga and Xtandi into standard of care for advanced, metastatic prostate cancer benefits many patients; however, all will ultimately become resistant to these medicines.
- Resistance mechanisms to these treatments remain mainly unknown.
- Dr. Van Allen will interrogate numerous potential resistance mechanisms by determining genomic alterations that occur prior to, and after resistance to Zytiga.
What this means for patients: Understanding mechanisms of resistance to Zytiga should result in the identification of new therapeutic targets for the treatment of drug-resistant, advanced, metastatic prostate cancer.
2013 Albert Fuss PCF Young Investigator Sponsored by Mark Shenkman
Eliezer Van Allen, MD
Dana-Farber Cancer Center
Levi Garraway, MD, PhD
Dissecting clinical response and resistance to abiraterone acetate (Zytiga)